Zhu Chen

Despite ADC’s raging success as oncology therapies, translational barriers still plague bioconjugate development, with pressure to enter the clinic quickly but preclinical activity not matching early clinical readouts.

As the field turns its attention to advance more non-traditional ADC translation, join this workshop to break down best strategy to balance depth of characterization against time, contextualized with reverse translational learnings to better advance ADCs to the clinic with confidence.   

Workshop highlights include:

• Leveraging reverse translation insights to streamline ADC preclinical efficacy assessment through intentional deployment of CDX and PDX models 
• Understanding when and how to position toxicity assessments for an integrated and balanced picture of ADC assets 
• Debating optimized strategies to balance preclinical characterization against time and cost to best advance ADCs to the clinic with confidence 
• Conducting translational studies to identify biomarkers for ADC sensitivity and resistance